October 23, 2015
The Government’s proposal to introduce a fixed costs regime for clinical negligence claims of up to £250,000 will almost certainly strike the death knell for access to justice for many negligently injured patients. It had previously been assumed that fixed recoverable costs were only being considered for cases where damages are awarded up to £100,000.…
Read More
July 23, 2015
The pharmaceutical regulatory field in Canada has seen a host of legislative and administrative developments in recent months. Many of the changes were introduced to provide Canada’s drug and health product watchdog, Health Canada, with greater powers to deal with public health risks associated with drugs and other health care products currently on the market…
Read More
July 21, 2015
In the world of U.S. pharmaceuticals, brand drug companies have a strong incentive to sue their generic rivals before generic products hit the market. Other than the obvious economic reasons, pre-launch litigation is built in to the very structure of the Hatch-Waxman Amendments (21 U.S.C. § 355). For an aspiring generic entrant, the promise of…
Read More
July 7, 2015
In May, 2015, the National Development and Reform Commission (“NDRC”), the Chinese authority in charge of price-related antitrust violations published the Notice on Reinforcing Supervision over Drug Prices (“Notice”). The Notice includes a range of specific issues on the supervision over drug price, including immediately launching special inspections into illegal conducts under the Pricing law…
Read More
June 15, 2015
Being the only Scandinavian jurisdiction which has ratified the Cape Town Convention, leasing companies and financiers have discovered that the Norwegian Civil Aircraft Registry provides for international security which is not available in other Scandinavian jurisdictions. The Cape Town Convention on International Interests in Mobile Equipment of 16 November 2001 and its Protocol on Matters…
Read More
